SCHEMBL7522071

SCHEMBL7522071

CCOC(=O)c1nn(-c2ccccc2)cc1[N+](=O)[O-]

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.67
RAB9A P51151 6/20 0.67
MAPT P10636 2/20 0.62
SMN1; SMN2 Q16637 4/20 0.55
ALDH1A1 P00352 4/20 0.55
NPSR1 Q6W5P4 2/20 0.55
NFKB1 P19838 2/20 0.55
NFKB2 Q00653 2/20 0.55
RELA Q04206 2/20 0.55
GLA P06280 1/20 0.55
KDM4E B2RXH2 3/20 0.53
POLB P06746 1/20 0.52
LMNA P02545 3/20 0.51
PTGS1 P23219 1/20 0.51
PTGS2 P35354 1/20 0.51
MAPK1 P28482 1/20 0.50
CHEK1 O14757 1/20 0.49
EGFR P00533 1/20 0.49
KDR P35968 1/20 0.49
GABRA2 P47869 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21069830 0.88 MAPT (0.63) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL19875273 0.87 MAPT (0.54) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL1639488 0.87 GAA (0.57) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL18039403 0.86 MAPT (0.53) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL11765148 0.82 MAPT (0.67) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL21070071 0.82 MAPT (0.55) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL4554346 0.81 NPC1 (0.77) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL12727135 0.81 MEN1 (0.48) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL1640182 0.81 MAPT (0.50) NPC1RAB9AMAPTSMN1; SMN2ALDH1A1
SCHEMBL8302429 0.80 LMNA (0.61) MAPTSMN1; SMN2ALDH1A1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP disclosed
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US disclosed
US-8623866-B2 2014-01-07 US disclosed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 EP disclosed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 WO disclosed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS PDE10A, PDE3A, PDE2A NPC1 1285/4885RAB9A 143/4885MAPT 4100/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.